Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment.
COVID-19
Molnupiravir
SARS-CoV-2
antiviral drug
mutagenesis
Journal
Bioinformatics and biology insights
ISSN: 1177-9322
Titre abrégé: Bioinform Biol Insights
Pays: United States
ID NLM: 101467187
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
12
2021
accepted:
11
02
2022
entrez:
28
3
2022
pubmed:
29
3
2022
medline:
29
3
2022
Statut:
epublish
Résumé
As SARS-CoV-2 continues to evolve and spread with the emergence of new variants, interest in small molecules with broad-spectrum antiviral activity has grown. One such molecule, Molnupiravir (MOV; other names: MK-4482, EIDD-2801), a ribonucleoside analogue, has emerged as an effective SARS-CoV-2 treatment by inducing catastrophic viral mutagenesis during replication. However, there are growing concerns as MOV's potential to induce host DNA mutagenesis remains an open question. Analysis of RNA-seq data from SARS-CoV-2-infected MOV-treated golden hamster lung biopsies confirmed MOV's efficiency in stopping SARS-CoV-2 replication. Importantly, MOV treatment did not increase mutations in the host lung cells. This finding calls for additional mutation calls on host biopsies from more proliferative tissues to fully explore MOV's hypothesized mutagenic risk.
Identifiants
pubmed: 35342288
doi: 10.1177/11779322221085077
pii: 10.1177_11779322221085077
pmc: PMC8950025
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11779322221085077Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Curr Opin Virol. 2021 Oct;50:17-22
pubmed: 34271264
Genome Biol. 2019 Nov 19;20(1):242
pubmed: 31744515
J Biol Chem. 2021 Jul;297(1):100770
pubmed: 33989635
J Infect Dis. 2021 Oct 28;224(8):1443-1444
pubmed: 34255064
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Gigascience. 2021 Feb 16;10(2):
pubmed: 33590861
J Biol Chem. 2021 Jul;297(1):100867
pubmed: 34118236
Nature. 2021 Mar;591(7850):451-457
pubmed: 33561864
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Methods. 2018 Aug;15(8):591-594
pubmed: 30013048
Environ Mol Mutagen. 2022 Jan;63(1):37-63
pubmed: 35023215
Mutagenesis. 2018 Apr 13;33(2):179-193
pubmed: 29669112
Biomed Pharmacother. 2022 Feb;146:112517
pubmed: 34902743
J Infect Dis. 2021 Aug 2;224(3):415-419
pubmed: 33961695
Nat Struct Mol Biol. 2021 Sep;28(9):740-746
pubmed: 34381216
Signal Transduct Target Ther. 2021 Dec 2;6(1):410
pubmed: 34857753
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
N Engl J Med. 2022 Feb 10;386(6):592-593
pubmed: 34914869
Nat Med. 2021 Jan;27(1):45-48
pubmed: 33432173
Nat Commun. 2021 Jun 3;12(1):3309
pubmed: 34083527
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Basic Clin Pharmacol Toxicol. 2017 Sep;121 Suppl 3:78-92
pubmed: 28481423
Sci Transl Med. 2022 Jan 19;14(628):eabl7430
pubmed: 34941423
Signal Transduct Target Ther. 2021 Jun 9;6(1):226
pubmed: 34108440